Literature DB >> 22371425

A critical review of reports of endogenous psychedelic N, N-dimethyltryptamines in humans: 1955-2010.

Steven A Barker1, Ethan H McIlhenny, Rick Strassman.   

Abstract

Three indole alkaloids that possess differing degrees of psychotropic/psychedelic activity have been reported as endogenous substances in humans; N,N-dimethyltryptamine (DMT), 5-hydroxy-DMT (bufotenine, HDMT), and 5-methoxy-DMT (MDMT). We have undertaken a critical review of 69 published studies reporting the detection or detection and quantitation of these compounds in human body fluids. In reviewing this literature, we address the methods applied and the criteria used in the determination of the presence of DMT, MDMT, and HDMT. The review provides a historical perspective of the research conducted from 1955 to 2010, summarizing the findings for the individual compounds in blood, urine, and/or cerebrospinal fluid. A critique of the data is offered that addresses the strengths and weaknesses of the methods and approaches to date. The review also discusses the shortcomings of the existing data in light of more recent findings and how these may be overcome. Suggestions for the future directions of endogenous psychedelics research are offered.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22371425     DOI: 10.1002/dta.422

Source DB:  PubMed          Journal:  Drug Test Anal        ISSN: 1942-7603            Impact factor:   3.345


  26 in total

Review 1.  On the transmethylation hypothesis: stress, N,N-dimethyltryptamine, and positive symptoms of psychosis.

Authors:  Dionysios Grammenos; Steven A Barker
Journal:  J Neural Transm (Vienna)       Date:  2014-11-02       Impact factor: 3.575

Review 2.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

3.  Effects of N, N-Dimethyltryptamine on Rat Behaviors Relevant to Anxiety and Depression.

Authors:  Lindsay P Cameron; Charlie J Benson; Lee E Dunlap; David E Olson
Journal:  ACS Chem Neurosci       Date:  2018-04-24       Impact factor: 4.418

Review 4.  Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies.

Authors:  Rafael G Dos Santos; José Carlos Bouso; Jaime E C Hallak
Journal:  Ther Adv Psychopharmacol       Date:  2017-02-23

Review 5.  New Paradigms of Old Psychedelics in Schizophrenia.

Authors:  Danish Mahmood; Sattam K Alenezi; Md Jamir Anwar; Faizul Azam; Kamal A Qureshi; Mariusz Jaremko
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-23

Review 6.  N,N-dimethyltryptamine and Amazonian ayahuasca plant medicine.

Authors:  Edward James; Joachim Keppler; Thomas L Robertshaw; Ben Sessa
Journal:  Hum Psychopharmacol       Date:  2022-02-17       Impact factor: 2.130

Review 7.  Insights into S-adenosyl-l-methionine (SAM)-dependent methyltransferase related diseases and genetic polymorphisms.

Authors:  Jiaojiao Li; Chunxiao Sun; Wenwen Cai; Jing Li; Barry P Rosen; Jian Chen
Journal:  Mutat Res Rev Mutat Res       Date:  2021-10-07       Impact factor: 7.015

Review 8.  A possibly sigma-1 receptor mediated role of dimethyltryptamine in tissue protection, regeneration, and immunity.

Authors:  Ede Frecska; Attila Szabo; Michael J Winkelman; Luis E Luna; Dennis J McKenna
Journal:  J Neural Transm (Vienna)       Date:  2013-04-26       Impact factor: 3.575

Review 9.  Neuropharmacology of N,N-dimethyltryptamine.

Authors:  Theresa M Carbonaro; Michael B Gatch
Journal:  Brain Res Bull       Date:  2016-04-25       Impact factor: 4.077

10.  Pharmacokinetic interactions between monoamine oxidase A inhibitor harmaline and 5-methoxy-N,N-dimethyltryptamine, and the impact of CYP2D6 status.

Authors:  Xi-Ling Jiang; Hong-Wu Shen; Donald E Mager; Ai-Ming Yu
Journal:  Drug Metab Dispos       Date:  2013-02-07       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.